Binkie4
Senior Member (Voting Rights)
I came across this.
COVID-19 and Ehlers-Danlos Syndrome: The Dangers of the Spike
Protein of SARS-CoV-2
This article describes the effect of the spike protein from both covid and the covid vaccine on those with Ehlers Danlos syndrome.
CONCLUSION
Regarding SARS-CoV-2 infection and vaccine injections) in people with EDS, we can conclude that although
EDS is a rare genetic pathology, with an overall incidence of approximately 1 in 5000 people (highly variable inci-
dence depending on the type of EDS), we have observed that a very high number of people suffering from the most
severe cases of long COVID (post-infection or post-vaccination sequelae) presented with EDS. As mentioned earlier,
EDS is systemic and directly linked to abnormalities in the connective tissue of genetic origin (production of colla-
gen). It seems to us quite possible that the deficiency in proteins of the extracellular matrix, which target membrane
integrins, confers an exacerbated "sensitivity" to the viral or vaccine Spike protein also capable of targeting integrins,
potentially leading to cell death, via caspase-3 or other activation. Notably, the Spike protein binds to alpha-5 beta-1
and alpha-V beta-3 integrins, which are integrins also targeted by collagen (partially denatured, exposing its cryp
tic/hidden RGD motifs), being deficient in people with EDS. Thus, it seems to us that any anti-Covid-19 vaccination
booster for these high-risk people is not desirable, the benefit/risk balance being extremely unfavorable. In the case of
SARS-CoV-2 infection, early outpatient treatment (e.g., high vitamin D supplementation) of these people seems appropriate.
COVID-19 and Ehlers-Danlos Syndrome: The Dangers of the Spike
Protein of SARS-CoV-2
This article describes the effect of the spike protein from both covid and the covid vaccine on those with Ehlers Danlos syndrome.
CONCLUSION
Regarding SARS-CoV-2 infection and vaccine injections) in people with EDS, we can conclude that although
EDS is a rare genetic pathology, with an overall incidence of approximately 1 in 5000 people (highly variable inci-
dence depending on the type of EDS), we have observed that a very high number of people suffering from the most
severe cases of long COVID (post-infection or post-vaccination sequelae) presented with EDS. As mentioned earlier,
EDS is systemic and directly linked to abnormalities in the connective tissue of genetic origin (production of colla-
gen). It seems to us quite possible that the deficiency in proteins of the extracellular matrix, which target membrane
integrins, confers an exacerbated "sensitivity" to the viral or vaccine Spike protein also capable of targeting integrins,
potentially leading to cell death, via caspase-3 or other activation. Notably, the Spike protein binds to alpha-5 beta-1
and alpha-V beta-3 integrins, which are integrins also targeted by collagen (partially denatured, exposing its cryp
tic/hidden RGD motifs), being deficient in people with EDS. Thus, it seems to us that any anti-Covid-19 vaccination
booster for these high-risk people is not desirable, the benefit/risk balance being extremely unfavorable. In the case of
SARS-CoV-2 infection, early outpatient treatment (e.g., high vitamin D supplementation) of these people seems appropriate.
Last edited by a moderator: